ELAHERE for the Treatment of Ovarian Cancer, US
ELAHERE is an ADC targeting the FRα cell-surface protein found at high levels in ovarian cancer.
You have successfully submitted your enquiry. Someone from our company will respond ASAP
Hoffmann-La Roche Ltd (Roche) is a world leader in biotechnology and a top provider of in-vitro diagnostics and other innovative healthcare solutions. The company strives to develop healthcare solutions for cardiometabolic diseases, inflammatory bowel diseases, hematologic disorders, infectious diseases, cancer, neurological disorders, respiratory diseases, gynaecological diseases, and ophthalmic diseases. To develop new solutions that help patients live longer and lead better lives, the company endeavours to strengthen its R&D efforts and enter into partnerships with external players. The company offers its products and services to hospitals, commercial laboratories, healthcare professionals, researchers, and pharmacists.
ELAHERE is an ADC targeting the FRα cell-surface protein found at high levels in ovarian cancer.
VYLOY™ (zolbetuximab) is the first and only CLDN18.2-targeted therapy approved for the treatment of gastric cancer.